EA200970600A1 - Композиция с замедленным высвобождением и способ её получения - Google Patents

Композиция с замедленным высвобождением и способ её получения

Info

Publication number
EA200970600A1
EA200970600A1 EA200970600A EA200970600A EA200970600A1 EA 200970600 A1 EA200970600 A1 EA 200970600A1 EA 200970600 A EA200970600 A EA 200970600A EA 200970600 A EA200970600 A EA 200970600A EA 200970600 A1 EA200970600 A1 EA 200970600A1
Authority
EA
Eurasian Patent Office
Prior art keywords
physiologically active
lactic acid
active substance
microcapsule
release
Prior art date
Application number
EA200970600A
Other languages
English (en)
Other versions
EA016176B1 (ru
Inventor
Томомити Футо
Казухиро Саито
Тецуо Хосино
Масухиса Хори
Original Assignee
Такеда Фармасьютикал Компани Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39015849&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200970600(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Такеда Фармасьютикал Компани Лимитед filed Critical Такеда Фармасьютикал Компани Лимитед
Publication of EA200970600A1 publication Critical patent/EA200970600A1/ru
Publication of EA016176B1 publication Critical patent/EA016176B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nanotechnology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Manufacturing Of Micro-Capsules (AREA)

Abstract

Предложены композиции с замедленным высвобождением, где растворимый в воде физиологически активный пептид, по существу, равномерно распределен в микрокапсуле, состоящей из полимера молочной кислоты или ее соли, и физиологически активное вещество содержится в количестве от 15 до 35% мас./мас. от общей массы микрокапсулы, и средневзвешенная молекулярная масса (Mw) полимера молочной кислоты составляет приблизительно от 11000 до приблизительно 27000, которые отличаются наличием высокого содержания физиологически активного вещества, и подавлением исходного избыточного высвобождения в течение одних суток после введения и стабильным замедленным высвобождением лекарственного средства в течение длительного периода времени, и способ их получения.
EA200970600A 2006-12-18 2007-12-17 Композиция с замедленным высвобождением и способ её получения EA016176B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87536406P 2006-12-18 2006-12-18
US91740107P 2007-05-11 2007-05-11
PCT/JP2007/074617 WO2008075762A1 (en) 2006-12-18 2007-12-17 Sustained-release composition and method for producing the same

Publications (2)

Publication Number Publication Date
EA200970600A1 true EA200970600A1 (ru) 2009-12-30
EA016176B1 EA016176B1 (ru) 2012-02-28

Family

ID=39015849

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970600A EA016176B1 (ru) 2006-12-18 2007-12-17 Композиция с замедленным высвобождением и способ её получения

Country Status (27)

Country Link
US (3) US8921326B2 (ru)
EP (1) EP2094246B1 (ru)
JP (2) JP4564098B2 (ru)
KR (1) KR101522035B1 (ru)
CN (1) CN101563068B (ru)
AR (1) AR064381A1 (ru)
AU (1) AU2007335406B2 (ru)
BR (1) BRPI0720582B1 (ru)
CA (1) CA2671670C (ru)
CL (1) CL2007003658A1 (ru)
CO (1) CO6180498A2 (ru)
CR (1) CR10867A (ru)
DO (1) DOP2009000144A (ru)
EA (1) EA016176B1 (ru)
EC (1) ECSP099439A (ru)
ES (1) ES2791698T3 (ru)
GE (1) GEP20125597B (ru)
IL (1) IL198845A (ru)
MA (1) MA31006B1 (ru)
MX (1) MX2009006653A (ru)
MY (1) MY148370A (ru)
NO (1) NO347209B1 (ru)
NZ (1) NZ577281A (ru)
PE (1) PE20081842A1 (ru)
TN (1) TN2009000197A1 (ru)
TW (1) TWI481424B (ru)
WO (1) WO2008075762A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2791698T3 (es) 2006-12-18 2020-11-05 Takeda Pharmaceuticals Co Composición de liberación sostenida y método para producir la misma
AR079657A1 (es) * 2009-12-22 2012-02-08 Takeda Pharmaceutical Formulacion de liberacion sostenida
EA021663B1 (ru) * 2010-06-25 2015-08-31 Такеда Фармасьютикал Компани Лимитед Композиция с замедленным высвобождением, способ ее получения и способ лечения рака
WO2013161778A1 (ja) * 2012-04-24 2013-10-31 国立大学法人大阪大学 薬剤ナノ粒子を分散した水分散液の製造法およびその利用
KR101558083B1 (ko) * 2014-04-07 2015-10-07 에스케이케미칼주식회사 약물함유 고분자미립구 제조방법
EA201692083A1 (ru) 2014-04-16 2017-03-31 Вейкс-Фарма Гмбх Фармацевтическая композиция для ветеринарии и ее применение
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
WO2019066649A1 (en) * 2017-09-26 2019-04-04 Nanomi B.V. PROCESS FOR THE PREPARATION OF MICROPARTICLES BY A DOUBLE EMULSION TECHNIQUE
KR101936040B1 (ko) * 2018-04-23 2019-01-08 주식회사 씨트리 안정화된 단상 혼합액을 이용하는 생분해성 미립구의 제조방법
WO2020196946A1 (ko) 2019-03-26 2020-10-01 노벨파마 주식회사 지속형 지방산 결합 GnRH 유도체 및 이를 포함하는 약제학적 조성물
CA3143471C (en) * 2019-07-12 2023-10-31 Heeyong Lee Long-lasting formulation containing rivastigmine, and method for preparing same

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3297033A (en) * 1963-10-31 1967-01-10 American Cyanamid Co Surgical sutures
US3565869A (en) * 1968-12-23 1971-02-23 American Cyanamid Co Extrudable and stretchable polyglycolic acid and process for preparing same
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3755558A (en) * 1971-02-23 1973-08-28 Du Pont Polylactide drug mixtures for topical application atelet aggregation
US3839297A (en) * 1971-11-22 1974-10-01 Ethicon Inc Use of stannous octoate catalyst in the manufacture of l(-)lactide-glycolide copolymer sutures
US3912692A (en) * 1973-05-03 1975-10-14 American Cyanamid Co Process for polymerizing a substantially pure glycolide composition
US3890283A (en) * 1973-06-04 1975-06-17 American Cyanamid Co Process for post-polymerizing polyglycolic acid
US4258063A (en) * 1978-06-23 1981-03-24 Henkel Corporation Self-emulsifying cosmetic base
US4249531A (en) * 1979-07-05 1981-02-10 Alza Corporation Bioerodible system for delivering drug manufactured from poly(carboxylic acid)
US4273920A (en) * 1979-09-12 1981-06-16 Eli Lilly And Company Polymerization process and product
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US5366734A (en) * 1981-02-16 1994-11-22 Zeneca Limited Continuous release pharmaceutical compositions
US4479911A (en) * 1982-01-28 1984-10-30 Sandoz, Inc. Process for preparation of microspheres and modification of release rate of core material
US4605730A (en) * 1982-10-01 1986-08-12 Ethicon, Inc. Surgical articles of copolymers of glycolide and ε-caprolactone and methods of producing the same
US4539981A (en) * 1982-11-08 1985-09-10 Johnson & Johnson Products, Inc. Absorbable bone fixation device
FR2537980B1 (fr) * 1982-12-17 1986-12-19 Sandoz Sa Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation
CH656884A5 (de) * 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
JPH0678425B2 (ja) 1984-07-06 1994-10-05 和光純薬工業株式会社 重合体の新規製造法
CA1256638A (en) * 1984-07-06 1989-06-27 Motoaki Tanaka Polymer and its production
ATE61935T1 (de) 1985-02-07 1991-04-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
JP2551756B2 (ja) * 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
MY107937A (en) * 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
JP2653255B2 (ja) 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
FR2658432B1 (fr) 1990-02-22 1994-07-01 Medgenix Group Sa Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation.
DE69129770T2 (de) * 1990-04-13 1998-11-19 Takeda Chemical Industries Ltd Biologisch abbaubare hochmolekulare Polymere, ihre Herstellung und ihre Verwendung
JP3116311B2 (ja) * 1990-06-13 2000-12-11 エーザイ株式会社 マイクロスフィアの製法
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
ES2110573T3 (es) * 1992-08-07 1998-02-16 Takeda Chemical Industries Ltd Produccion de microcapsulas de farmacos solubles en agua.
JP3277342B2 (ja) * 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
DE4342092B4 (de) 1993-12-09 2007-01-11 Zentaris Gmbh Langwirkende Injektionssuspension und Verfahren zur Herstellung
JP3490171B2 (ja) 1994-02-21 2004-01-26 武田薬品工業株式会社 生体内分解性ポリマーの末端カルボキシル基におけるエステル
EP0668073B1 (en) 1994-02-21 1999-04-14 Takeda Chemical Industries, Ltd. Polyester matrix for a pharmaceutical sustained-release preparation
JPH07273447A (ja) 1994-03-29 1995-10-20 Sumitomo Kinzoku Ceramics:Kk セラミック回路基板及びその製造方法
US5763513A (en) * 1994-05-19 1998-06-09 Mitsui Toatsu Chemicals, Inc. L-lactic acid polymer composition, molded product and film
FR2736508B1 (fr) 1995-07-13 1997-09-19 Francais Prod Ind Cfpi Nouvelle forme solide de stockage et de commercialisation pour compositions phytosanitaires et moyens pour sa preparation
TW448055B (en) * 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
CA2192782C (en) * 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
CA2192773C (en) * 1995-12-15 2008-09-23 Hiroaki Okada Production of sustained-release preparation for injection
PT839525E (pt) * 1996-10-31 2004-10-29 Takeda Chemical Industries Ltd Preparacao de libertacao prolongada
JPH10273447A (ja) 1997-01-29 1998-10-13 Takeda Chem Ind Ltd 徐放性マイクロスフィア、その製造法および用途
WO1998032423A1 (en) 1997-01-29 1998-07-30 Takeda Chemical Industries, Ltd. Sustained-release microspheres, their production and use
US5945126A (en) * 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
GB9718986D0 (en) 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
JPH11269094A (ja) 1998-01-16 1999-10-05 Takeda Chem Ind Ltd 徐放性組成物、その製造法および用途
AU758596B2 (en) * 1998-01-16 2003-03-27 Takeda Pharmaceutical Company Limited Sustained release compositions, process for producing the same and utilization thereof
ES2214013T3 (es) 1998-03-04 2004-09-01 Takeda Chemical Industries Ltd Preparacion de liberacion sostenida para un antagonista de aii, su produccion y su uso.
US6114495A (en) * 1998-04-01 2000-09-05 Cargill Incorporated Lactic acid residue containing polymer composition and product having improved stability, and method for preparation and use thereof
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6270802B1 (en) * 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
ATE289205T1 (de) * 1998-12-15 2005-03-15 Takeda Pharmaceutical Verfahren zur herstellung biologisch-abbaubarer polyester
CA2378714A1 (en) * 1999-07-15 2001-01-25 Takeda Chemical Industries, Ltd. Sustained release compositions, methods for producing the same and uses thereof
AU6510400A (en) 1999-08-04 2001-03-05 Oakwood Laboratories L.L.C. Slow release microspheres
PT1693054T (pt) 2000-08-07 2016-07-07 Takeda Pharmaceuticals Co Polímero de ácido láctico e processo para a sua produção
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
WO2002043766A1 (fr) 2000-11-29 2002-06-06 Takeda Chemical Industries, Ltd. Compositions medicinales et leur procede de preparation
AU2002221139A1 (en) 2000-12-15 2002-06-24 Takeda Chemical Industries Ltd. Medicinal compositions of nonpeptidyl gonadotropin-releasing hormone agonist or antagonist, process for producing the same and use thereof
TWI225416B (en) * 2001-06-29 2004-12-21 Takeda Chemical Industries Ltd Sustained-release composition and process for producing the same
TWI332407B (en) * 2001-06-29 2010-11-01 Takeda Chemical Industries Ltd Controlled release composition and method of producting the same
CN1620285A (zh) * 2001-12-26 2005-05-25 武田药品工业株式会社 新微球和其生产方法
PT1532985T (pt) * 2002-06-25 2017-01-20 Takeda Pharmaceuticals Co Processo de produção de uma composição de libertação sustentada
US6803708B2 (en) * 2002-08-22 2004-10-12 Cdream Display Corporation Barrier metal layer for a carbon nanotube flat panel display
EP1660039B1 (en) * 2003-07-18 2016-09-28 Oakwood Laboratories L.L.C. Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions
CN100588423C (zh) 2003-07-23 2010-02-10 Pr药品有限公司 控释组合物
US20050152911A1 (en) * 2003-09-24 2005-07-14 Montana State University Norovirus monoclonal antibodies and peptides
TW200613012A (en) * 2004-07-02 2006-05-01 Takeda Pharmaceuticals Co Sustained-release composition, process for producing the same and use of the same
BRPI0516830A (pt) 2004-10-01 2008-09-23 Ramscor Inc composições de droga de liberação sustentada convenientemente implantáveis
PT1824460E (pt) 2004-11-10 2015-01-14 Tolmar Therapeutics Inc Um sistema de administração polimérico estabilizado
ES2791698T3 (es) 2006-12-18 2020-11-05 Takeda Pharmaceuticals Co Composición de liberación sostenida y método para producir la misma

Also Published As

Publication number Publication date
JP4564098B2 (ja) 2010-10-20
IL198845A (en) 2015-07-30
ECSP099439A (es) 2009-07-31
KR101522035B1 (ko) 2015-05-20
DOP2009000144A (es) 2009-07-30
CN101563068A (zh) 2009-10-21
JP5258844B2 (ja) 2013-08-07
BRPI0720582B1 (pt) 2021-08-24
WO2008075762A1 (en) 2008-06-26
NO20092662L (no) 2009-09-07
CL2007003658A1 (es) 2008-05-09
JP2010513225A (ja) 2010-04-30
AR064381A1 (es) 2009-04-01
US9617303B2 (en) 2017-04-11
TN2009000197A1 (en) 2010-10-18
JP2010222371A (ja) 2010-10-07
EP2094246B1 (en) 2020-04-01
CR10867A (es) 2009-07-30
US20110135741A1 (en) 2011-06-09
TW200833376A (en) 2008-08-16
KR20090094272A (ko) 2009-09-04
NZ577281A (en) 2011-12-22
ES2791698T3 (es) 2020-11-05
CO6180498A2 (es) 2010-07-19
EA016176B1 (ru) 2012-02-28
CA2671670A1 (en) 2008-06-26
US20150080322A1 (en) 2015-03-19
US8921326B2 (en) 2014-12-30
CN101563068B (zh) 2013-03-20
PE20081842A1 (es) 2009-01-19
AU2007335406B2 (en) 2012-09-13
MX2009006653A (es) 2009-07-02
US9713595B2 (en) 2017-07-25
IL198845A0 (en) 2010-02-17
BRPI0720582A2 (pt) 2014-02-04
MY148370A (en) 2013-04-15
US20170165204A1 (en) 2017-06-15
EP2094246A1 (en) 2009-09-02
AU2007335406A1 (en) 2008-06-26
NO347209B1 (no) 2023-07-03
GEP20125597B (en) 2012-08-10
CA2671670C (en) 2015-02-10
MA31006B1 (fr) 2009-12-01
TWI481424B (zh) 2015-04-21

Similar Documents

Publication Publication Date Title
EA200970600A1 (ru) Композиция с замедленным высвобождением и способ её получения
ATE424848T1 (de) Pharmazeutische zusammensetzungen für die kontrollierte freigabe von biologischen wirkstoffen
WO2008157614A3 (en) Sustained intraocular delivery of drugs from biodegradable polymeric microparticles
MXPA05012791A (es) Formulacion sostenida que contiene dimeticona.
CY1105071T1 (el) Συνθεση ελεγχομενης απελευθερωσης και μεθοδος παρασκευης αυτης
EA200800161A1 (ru) Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций
RU2010149561A (ru) Твердое лекарственное средство с замедленным высвобождением действующих веществ
ATE493973T1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
PE20071139A1 (es) Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-co-glicolido
JP2010518086A5 (ru)
CA2468703A1 (en) Controlled release polymeric compositions of bone growth promoting compounds
RS54543B1 (en) Fast acting gastric acid secretion inhibitor
ATE438385T1 (de) Pharmazeutische zusammensetzung
Guggi et al. Matrix tablets based on thiolated poly (acrylic acid): pH-dependent variation in disintegration and mucoadhesion
EA201200185A1 (ru) Фармацевтическая композиция для пероральной доставки дииндолилметана
UA97396C2 (ru) Фармацевтическая композиция пролонгированного высвобождения, содержащая пасиреотид памоат в микрочастицах
WO2005123034A8 (en) Microparticulate systems for the oral administration of biologically active substances
TN2009000476A1 (en) Slow release pharmaceutical composition made of microparticles
Yang et al. Pathogenesis and treatment of wound healing in patients with diabetes after tooth extraction
UA114088C2 (xx) Лікарська композиція з пролонгованим вивільненням для ін'єкцій
WO2008055254A3 (en) Formulations and methods for oral delivery of proteins
UA97125C2 (ru) Композиция продолжительного высвобождения и способ ее получения
EA200701525A1 (ru) Фармацевтическая полимерная композиция для перорального введения тербуталина сульфата с контролируемым высвобождением
RU2011108370A (ru) Жевательная композиция, включающая альгинат, бикарбонат и карбонат
TH120965B (th) องค์ประกอบที่มีการปลดปล่อยแบบทยอยและวิธีการสำหรับการผลิตองค์ประกอบ

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM